Quick Answer
Co-Diagnostics, Inc. reported Total Revenue of $622.5 thousand for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -84.1% in Total Revenue from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $2.5 thousand | Q2 2017: $2.5 thousand | Q3 2017: $2.6 thousand | Q3 2017: $2.6 thousand | Q1 2018: $9.7 thousand | Q1 2018: $9.7 thousand | Q2 2018: $9.7 thousand | Q3 2018: $9.7 thousand | Q1 2019: $3.4 thousand | Q2 2019: $61.6 thousand | Q3 2019: $41.4 thousand | Q1 2020: $1.55 million | Q2 2020: $24.04 million | Q3 2020: $21.82 million | Q1 2021: $20.02 million | Q2 2021: $27.36 million | Q3 2021: $30.10 million | Q1 2022: $22.70 million | Q2 2022: $5.02 million | Q3 2022: $5.09 million | Q1 2023: $602.0 thousand | Q2 2023: $197.8 thousand | Q3 2023: $2.46 million | Q1 2024: $467.9 thousand | Q2 2024: $2.66 million | Q3 2024: $641.1 thousand | Q1 2025: $50.3 thousand | Q2 2025: $162.9 thousand | Q3 2025: $145.4 thousand.
- Over the full 9 years of available data (2017 to 2025), Co-Diagnostics, Inc.'s Total Revenue has grown by 8,024.4%.
- Historical annual values: Fiscal year 2025: $622.5 thousand | Fiscal year 2024: $3.92 million | Fiscal year 2023: $6.81 million | Fiscal year 2022: $34.22 million | Fiscal year 2021: $97.89 million | Fiscal year 2020: $74.55 million | Fiscal year 2019: $215.0 thousand | Fiscal year 2018: $39.9 thousand | Fiscal year 2017: $7.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: